• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Pharmacy Research
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 9 (2025)
Volume Volume 8 (2024)
Volume Volume 7 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 6 (2022)
Volume Volume 5 (2021)
Volume Volume 4 (2020)
Volume Volume 3 (2019)
Volume Volume 2 (2018)
Volume Volume 1 (2017)
Mohamed, D., Skran, W., Abo-zeid, Y. (2023). Application of Several Nano Carriers to Improve the Solubility and the Bioavailability of Carvedilol. Journal of Advanced Pharmacy Research, 7(1), 50-65. doi: 10.21608/aprh.2022.167884.1198
Doaa Mohamed; Wedad Skran; Yasmin Abo-zeid. "Application of Several Nano Carriers to Improve the Solubility and the Bioavailability of Carvedilol". Journal of Advanced Pharmacy Research, 7, 1, 2023, 50-65. doi: 10.21608/aprh.2022.167884.1198
Mohamed, D., Skran, W., Abo-zeid, Y. (2023). 'Application of Several Nano Carriers to Improve the Solubility and the Bioavailability of Carvedilol', Journal of Advanced Pharmacy Research, 7(1), pp. 50-65. doi: 10.21608/aprh.2022.167884.1198
Mohamed, D., Skran, W., Abo-zeid, Y. Application of Several Nano Carriers to Improve the Solubility and the Bioavailability of Carvedilol. Journal of Advanced Pharmacy Research, 2023; 7(1): 50-65. doi: 10.21608/aprh.2022.167884.1198

Application of Several Nano Carriers to Improve the Solubility and the Bioavailability of Carvedilol

Article 5, Volume 7, Issue 1, January 2023, Page 50-65  XML PDF (421.99 K)
Document Type: Review Article
DOI: 10.21608/aprh.2022.167884.1198
View on SCiNiTO View on SCiNiTO
Authors
Doaa Mohamed email ; Wedad Skranorcid ; Yasmin Abo-zeidorcid
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt.
Abstract
Hypertension (HTN) is one of our eight mortalities worldwide. Approximately one-third of the world's adult population suffers with hypertension (31.1 %, or 1.39 billion people). Hypertension prevalence varies. The World health organization (WHO) Region of the Americas has the lowest prevalence of hypertension (18%) and the WHO African Region has the highest prevalence of hypertension (27%) overall. In Egypt, according to WHO, Egypt estimated adult people suffer from hypertension in 2017 was (29.2%) and in 2020, total percent of death from hypertension (3.93%) of total death. Hypertension is described as disturbance in the circulatory system accompanied by a sustained increase in systolic and diastolic blood pressure to a level that is likely to have negative effects. The most popular hypertension types in people are first and second hypertension that need to adjust the life style and taken medications when these types not controlled. Several types of medications can be used to control HTN such as: Diuretics, Angiotensin converting enzymes inhibitors (ACEIs), Angiotensin receptor blockers (ARBs) calcium channel blockers (CCBs) and beta-blockers (BBs). All of them can be used as individually or in combination with each other to control blood pressure. Calcium channel blockers (CCBs) is one these drugs that used to HTN, classified to (first, second and third generation). carvedilol (CAR) is one of the most popular drugs that used in third generation.it has additional advantages rather than first and second generation that α1 –adrenergic receptors antagonist. CAR belongs to CCBs but has some drawbacks as low solubility, low bioavailability and hepatic metabolism that make it need to be taken several times in the day. Therefore, nano drug delivery system is used to overcome this draw backs, it can encapsulate lipophilic drugs in its core, deliver it to the site of action, enhancement solubility and the bioavailability of this lipophilic drugs. Many literatures published, attempt with several way of loaded CAR lipophilic drug into nanocarriers to increase it solubility, enhance its bioavailability and sustained CAR release compared with pure CAR. This review summarized all recent work that attempt to improve the solubility and bioavailability of CAR.
Keywords
Carvedilol; Nanomedicine; Hypertension; bioavailability
Main Subjects
Section C: Drug Design, Delivery & Targeting
Statistics
Article View: 537
PDF Download: 596
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.